Prospective, longitudinal cohort study of follow-up in patients with COVID-19 infection and requiring inpatient treatment for respiratory disease
Completed
- Conditions
- COVID-19
- Registration Number
- DRKS00027106
- Lead Sponsor
- niversitätsklinikum der RWTH Aachen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 278
Inclusion Criteria
Age of majority
Written declaration of consent
Persons who are legally competent and mentally able to able to follow the instructions of the study staff.
Exclusion Criteria
Younger than 18 years (20 years for Japanese nationality)
Pregnant and breastfeeding women (will be asked)
Immobility with need for care
Lack of maturity
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time till development of ARDS
- Secondary Outcome Measures
Name Time Method Pulmonary-related mortality<br>Duration of ventilation and hospitalisation for COVID-19<br>Time to ventilation<br>Time to sepsis<br>Time to non-cardiac death<br>Time to all-cause mortality<br>Time to non-fatal terminal renal failure renal failure<br>Time to development of heart failure (HFrEF)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie long-term respiratory outcomes in DRKS00027106 COVAS study participants with severe COVID-19?
How does COVAS observational data compare to standard-of-care outcomes for hospitalized COVID-19 patients in Germany?
What biomarkers correlate with improved survival in DRKS00027106's longitudinal cohort of post-acute respiratory disease patients?
What are the potential adverse events identified in COVAS follow-up of inpatient respiratory disease management for SARS-CoV-2 infections?
How does COVAS study's approach to post-COVID-19 respiratory monitoring compare to other observational trials like RECOVERY or TOGETHER?